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Abstract
Introduction The involvement of vitamin D receptor (VDR),
which is a key mediator in the vitamin D pathway, in breast
cancer etiology has long been of interest.
Methods We examined the association between
polymorphisms in the 3' end of the VDR gene, specifically BsmI
and Poly(A), and breast cancer risk within a large, population-
based, case-control study of breast cancer. Cases (n = 1,631)
were Caucasian and African-American women, aged 35 to 64
years, who were diagnosed with incident, invasive breast cancer
between July 1994 and April 1998. Control individuals (n =
1,435) were women without breast cancer ascertained through
random digit dialing.
Results Accounting for age, study site, and sampling weights,
we observed a significantly increased risk for breast cancer
among Caucasian, postmenopausal carriers of the bb genotype
of BsmI (odds ratio = 1.53, 95% confidence interval = 1.04 to
2.27). However, no associations with the bb genotype were
observed in African-American women. Overall, there were no
significant associations between the Poly(A)  genotype and
breast cancer risk in either racial group. Smoking status (ever/
never) modified the association between both the BsmI and
Poly(A)  genotypes and breast cancer risk. The respective
associations between these genotypes and breast cancer risk
did not significantly vary by oral contraceptive use, hormone
replacement therapy, or body mass index.
Conclusion Our results provide additional support for an
increased risk for breast cancer in postmenopausal Caucasian
women with the BsmI bb genotype and shed light on possible
differential effects by menopausal status and race.
BMI = body mass index; bp = base pairs; CARE = Contraceptive and Reproductive Experiences; HT = hormone therapy; OC = oral contraceptive; 
OR = odds ratio; PCR = polymerase chain reaction.Breast Cancer Research    Vol 9 No 6    Trabert et al.
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Introduction
Vitamin D is a key player in cell proliferation, differentiation, and
apoptosis in normal and malignant breast cells [1,2]. Indeed,
the active form of vitamin D is hypothesized to have antiprolif-
erative effects in many types of cells, including breast cancer
cells [3-6]. The observation of a reduced risk for breast cancer
among women with high vitamin D status lends support to this
hypothesis [3,4].
Vitamin D has also been established as a determinant of bone
density and, furthermore, higher bone density has been shown
to be associated with risk for developing breast cancer [7-9].
Whether the association between bone density and breast
cancer is directly related to vitamin D or is explained wholly or
in part by other factors such as the relationship of bone density
to endogenous hormones, particularly estrogen, remains
unclear.
The autocrine/paracrine pathway of vitamin D biosynthesis has
been implicated in breast cell carcinogenesis [1]. In this path-
way, when circulating 25-hydroxyvitamin D reaches the mam-
mary tissue it is further converted to 1,25-dihydroxyvitamin D
by endogenous 1-α-hydroxylase in the breast [1,2]. The locally
produced 1,25-dihydroxyvitamin D may bind to the vitamin D
receptor (VDR) and regulate cell development or progression
[2].
Both the 5' and 3' termini of the VDR gene exhibit sequence
level variation in the population. Three restriction fragment
length polymorphisms at the 3' end of the gene (BsmI, ApaI,
and TaqI restriction sites) have been observed to be in linkage
disequilibrium with one another and with the variable length
Poly(A)  sequence in the 3'-untranslated region [10-15].
Because of the key role that VDR plays in the vitamin D biosyn-
thesis pathway, it has been hypothesized that polymorphisms
within the VDR gene may modify the risk for breast cancer,
either singularly or through gene-gene or gene-environment
interactions.
The long sequence of Poly(A) has been associated with both
increased and decreased risks for breast cancer [10,16,17].
Additionally, variation in length of the Poly(A) tract has been
associated with prostate cancer risk in a subset of studies [12-
14]. Studies aimed at elucidating the association between the
BsmI polymorphism and breast cancer risk have reported pos-
itive [3,10,16], inverse [17], and null findings [18-20]. More
consistent associations have been observed between the
BsmI polymorphism and bone density [21,22].
The inconsistency in findings to date is not surprising because
most studies have been limited by sample size, and there has
been considerable heterogeneity in study designs. Moreover,
prior studies have focused on primarily Caucasian popula-
tions; hence, little is known about the association of VDR pol-
ymorphisms and breast cancer risk in African-American
women. The present study was undertaken to assess whether
VDR polymorphisms BsmI and Poly(A) are associated with
breast cancer risk in a large population-based case-control
study of Caucasian and African-American women aged 35 to
64 years.
Materials and methods
Study population
This study was conducted within the National Institute of Child
Health and Human Development's Women's Contraceptive
and Reproductive Experiences (CARE) study [23], the details
of which have been described elsewhere. In brief, five metro-
politan areas in the USA, including: Atlanta, Detroit, Los Ange-
les, Philadelphia, and Seattle, were included in this population-
based case-control study. Cases were ascertained by the Sur-
veillance, Epidemiology, and End Results population-based
cancer registries at four sites and by field staff monitoring
catchment area hospital records at the fifth site. Cases con-
sisted of Caucasian and African-American women aged 35 to
64 years, with no history of prior breast cancer, who were
diagnosed with invasive breast cancer between July 1994 and
April 1998. Two subgroups (younger cases [<50 years] and
African-American cases) were over-sampled to achieve a gen-
erally uniform distribution across race and age strata. Central-
ized random digit dialing was used to ascertain population-
based control individuals, consisting of women without breast
cancer, and selection fractions were designed to match case
interview frequencies within strata of study center, race, and 5-
year age group. A total of 4,575 cases (76.5% of those eligi-
ble) and 4,682 controls (78.6% of those eligible) completed
an in-person interview on breast cancer risk factors, including
family history.
Of interviewed women, 33% were sampled for blood collec-
tion based on available funding. The stratified sampling plan
for blood collection consisted of a blood sample from all cases
and controls with a first-degree family history of breast cancer
(affected mother, sister, or daughter) plus a random sample of
those without a first-degree family history. Random selection
for blood collection was based on sampling fractions specific
to study center, race, and 5-year age group to achieve a rela-
tively uniform distribution across strata. Of the 2,049 cases
and 1,949 controls selected for blood draw, 1,644 (80.2%)
cases and 1,451 (74.3%) controls donated a sample. This
represents 35.9% and 31.0% of all CARE cases and controls,
respectively. Among both cases and controls selected for
blood collection, the proportions who gave blood did not vary
by age. However, those who gave blood were proportionately
more likely than those who did not give blood to be Caucasian
(cases: 69.9% versus 42.0%, P < 0.001; controls: 68.6% ver-
sus 44.1%, P  < 0.001), to have attended college (cases:
59.9% versus 48.0%, P  < 0.001; controls: 57.2% versus
47.1%, P < 0.001), and to have local stage disease (63.5%
versus 56.7%, P = 0.03). Additionally, among only the con-
trols, those who gave blood were more likely than those whoAvailable online http://breast-cancer-research.com/content/9/6/R84
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did not to have a positive family history of breast cancer
(52.8% versus 43.6%, P = 0.001). The weighted sampling
probabilities used in these analyses should alleviate these dif-
ferences to some extent.
Of the 3,095 total blood samples, 3,066 samples (1,631
cases and 1,435 controls) provided genotyping data on one
or both of the VDR polymorphisms; the other 29 samples were
excluded because they did not provide data on either polymor-
phism. Study participants provided written informed consent
for the interview and for the use of specimens for laboratory
analysis.
Genotyping
The BsmI VDR polymorphism is located within intron 8 of the
gene. Initial PCR amplification involved 25 to 50 ng genomic
DNA, purified from whole blood using standard proteinase K,
phenol chloroform extraction methods [24]. The BsmI VDR
polymorphism was determined using PCR-restriction frag-
ment length polymorphism analysis, as we described previ-
ously [25]. PCR amplification of genomic DNA (25 ng) used
35 cycles with an annealing temperature of 66°C and the fol-
lowing primers: 5'-CAACCAAGACTACAAGTACCGCGT-
CAGTGA-3' and 5'-AACCAGCGGGAAGAGGTCAAGGG-
3'.
The resulting 800 base pair (bp) PCR product is then diluted
and digested with BsmI at 65°C for 18 hours using 5 units of
enzyme (Boehringer Mannheim, Penzberg, Germany) per 20
μl reaction. Following digestion, the PCR products were sep-
arated using 2% agarose gels containing ethidium bromide
and visualized under short-wave UV light. Fragments of 650
and 150 bp are visible if the 800 bp product is cut by the BsmI
restriction enzyme.
DNA from homozygote individuals (BB) lacking a BsmI restric-
tion site appeared on the gel as single 800 bp band. DNA from
homozygote individuals (bb) appeared as two well-separated
bands, 650 and 150 bp, indicating that the BsmI enzyme site
is present in both alleles. Heterozygotes (Bb) have three
bands: a 650 bp band and a 150 bp band (representing the
presence of the BsmI site in one allele) plus an 800 bp band
(indicating its absence in the other). Because the assay is
extremely robust and it is easy to detect heterozygotes as well
as both types of homozygotes, no additional quality control
procedures were implemented except water blanks to check
for sample contamination, standards to size restriction diges-
tion products, and orientation markers.
The VDR Poly(A) polymorphism was analyzed using a nested
PCR reaction [25]. In the first PCR reaction, genomic DNA
(25 ng) was amplified for 35 cycles with an annealing temper-
ature of 62°C and the following primers: 5'-GACAGAGGAG-
GGCGTG ACTC-3' and 5'-
GTGTAGTGAAAAGGACACCGGA-3'. For the nested PCR,
5 μl from a 1:200 dilution of the first PCR reaction was ampli-
fied in the presence of 2.5 pmol IR770dATP with the following
conditions: 94°C for 2 minutes, followed by 35 cycles with 30
seconds each at 94°C, 66°C, and 72°C, concluding with 3
minutes at 72°C. The primers were 5'-GAGACCAACCT-
GACCA-3' and 5'-CCTCAGCCTCCTGAGT-3'.
The PCR products were resolved on a Li-Cor Model 4200
automated infrared DNA sequencer (Li-Cor, Lincoln, NE,
USA). Genotypes were assigned with commercially available
SAGA software (Li-Cor). Allele sizes are scored by compari-
son with known control sizes and confirmed by rerunning with
additional samples of known size.
Statistical methods
Sampling weights were computed by dividing the total number
of women interviewed in each of the 240 strata (defined by
case-control status, age [5-year age categories], race [Afri-
can-American, Caucasian], study site, and first-degree family
history of breast cancer [present, absent]) by the number of
women sampled for the genotyping. These weights allowed
results from tested samples to be adjusted so that they repre-
sented the proportions and effects expected if the entire
CARE study population had been tested, and were used to
calculate weighted proportions and weighted odds ratios
(ORs). These methods were described previously [26].
The Pearson χ2 test was used to check Hardy-Weinberg equi-
librium and to compare case and control distributions across
covariate categories. The correlation coefficient r was used as
the estimate of pair-wise linkage disequilibrium between BsmI
and Poly(A) alleles in control women. Associations between
VDR polymorphisms and breast cancer risk were estimated
using unconditional logistic regression controlling for match-
ing factors (age, study site, and race) and sampling weights.
The BsmI BB and short Poly(A) SS genotypes were chosen
as the respective referent categories based on published liter-
ature [10,16,19]. As reported previously, women were consid-
ered menopausal if they had known menopause (natural,
induced, or type unclear) or assumed natural menopause [27].
Known or suspected risk factors for breast cancer (including
menopausal status, first-degree family history of breast cancer,
body mass index [BMI], parity, breast-feeding history, hormone
therapy [HT] use [ever, former, and current use of unopposed
estrogen as well as combined estrogen and progestin], oral
contraceptive [OC] use [ever, former, and current use as well
as duration], education, alcohol consumption, smoking, and
physical activity) were evaluated for potential confounding
effects. BMI was defined using World Health Organization cut
points, and smoking was dichotomized as ever smokers and
never smokers. The overwhelming majority (90.6%) of ever
smokers reported lifetime smoking of at least one pack-year,
whereas only 1.2% of ever smokers smoked 0.1 lifetime pack-
years or fewer. A variable was classified as a confounding fac-
tor if the addition of the individual covariate to the baselineBreast Cancer Research    Vol 9 No 6    Trabert et al.
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model resulted in more than a 10% change in the OR
estimate.
We examined age, race, menopausal status and family history
of breast cancer for potential modifying effects on the associ-
ation between VDR polymorphisms and breast cancer risk. In
addition, given prior reports of the possible shared etiology of
breast cancer and bone density, we assessed the potential
modifying effects of a subset of breast cancer risk factors, spe-
cifically OC use among premenopausal women, HT use
among postmenopausal women, smoking, and BMI, that are
also known or suspected of having an effect on bone mineral
density. Effect modification was explored in stratified models
as well as in models using multiplicative interaction terms. In
the multiplicative interaction models, a variable was consid-
ered an effect modifier if the P value for the interaction terms
was less than or equal to 0.05. All models in which effect mod-
ification was explored were initially stratified by race, a match-
ing variable, and menopausal status because of existing effect
modification.
Statistical analyses were performed using Stata/SE® software
(Version 9.2 for Windows; StataCorp LP, College Station, TX,
USA). The study protocol was approved by institutional review
boards at participating centers.
Results
Table 1 shows the distribution of demographic and family his-
tory characteristics within the sampled study population with
data for one or both of the VDR polymorphisms (n = 3,066).
As expected by design, cases were similar to controls with
regard to age and race, and the proportions with first-degree
family history in our sampled group (37.4% cases and 23.6%
controls) exceeded those in the underlying CARE study
(17.0% cases and 9.7% controls). All subsequent analyses
account for the sampled nature of the data, including the over-
sampling of women with a first-degree family history of breast
cancer, through sampling weight adjustment. For Poly(A),
there was excellent observer agreement in the 6% of randomly
selected duplicates of genotyping results that were included
for quality control purposes (κ statistic of 0.99). Similar infor-
mation was not collected for BsmI. Laboratory personnel were
blinded to case-control status.
We did not observe deviation from the expected Hardy-Wein-
berg frequencies for the Poly(A) genotypes in the controls (P
= 0.69, P = 0.47, and P = 0.48 for combined controls, Cau-
casian controls, and African-American controls, respectively).
However, we did observe significant deviation for the BsmI
genotype (P < 0.01, P < 0.01, and P = 0.03 for combined
controls, Caucasian controls, and African-American controls,
respectively). BsmI and Poly(A) genotypes were in linkage
disequilibrium for the Caucasian but not the African-American
population (Caucasian: r2  = 0.84; African American: r2 =
0.47).
BsmI and Poly(A) genotypes and breast cancer risk
We found relatively similar VDR polymorphism genotype fre-
quencies in cases and controls (Table 2). Allelic frequencies in
Caucasians were similar to those reported in other Caucasian
populations (data not shown) [10,16,18]. We did not observe
any associations between polymorphisms in BsmI or Poly(A)
and breast cancer risk for the combined study population
(overall and within racial groups) after controlling for sampling
weights and matching factors: age, race, and study site. Simi-
larly, we did not observe any associations between polymor-
phisms in BsmI or Poly(A) and breast cancer risk within strata
of tumor stage, grade, histology, or receptor status (data not
shown). After controlling for many known and suspected risk
factors for breast cancer, we found no evidence that any of the
variables mentioned above acted as confounding factors of
these results. However, given the established variation in
breast cancer risk factor profiles by menopausal status and
because of the difference in the direction of the ORs by race,
all further results are stratified by menopausal status and race
(Table 3).
The BsmI genotype was not associated with breast cancer
risk in premenopausal Caucasian women or in African-Ameri-
can women. Among postmenopausal Caucasian women, the
risk for breast cancer was increased in women carrying the
homozygous bb genotype as compared with carriers of the BB
genotype (OR = 1.5, 95% confidence interval [CI] = 1.0 to
2.3) and, although not statistically significant, the risk in
women carrying the heterozygous Bb genotype was also
increased (OR = 1.2, 95% CI = 0.8 to 1.8). A trend of increas-
ing risk with increasing number of b alleles carried was statis-
tically significant (P for trend = 0.03). We did not observe a
significant association with breast cancer in any racial-meno-
pausal status subgroup in relation to the Poly(A) polymor-
phism.
Because the Poly(A) and BsmI genotypes among African-
American women were not in linkage disequilibrium, we
explored the combined effects of the Poly(A) and BsmI geno-
types in this subpopulation (results not shown). An increased
or decreased risk for breast cancer was not associated with
the combination of the Poly(A) and BsmI genotypes. Stratify-
ing or adjusting for age, menopausal status, or family history of
breast cancer did not alter significantly the observed absence
of association.
BsmI and Poly(A) genotypes, effect modification, and 
breast cancer risk
Effect modification of the relationship of either genotype with
risk for breast cancer by a priori hypothesized potential effect
modifiers (namely OC use, HT use, BMI, family history, and
age), as well as stratification by tumor characteristic (grade,
histology, stage, estrogen/progesterone receptor status) was
not meaningful. Smoking was the only a priori hypothesized
potential effect modifier that significantly modified the associ-Available online http://breast-cancer-research.com/content/9/6/R84
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Table 1
Sociodemographic characteristics, family history of breast cancer, and hormone use among cases and controls
Characteristics Cases (n = 1,631) Controls (n = 1,435)
Age (years)a
35 to 39 306 (18.8) 230 (16.0)
40 to 44 243 (14.9) 246 (17.1)
45 to 49 260 (15.9) 236 (16.5)
50 to 54 295 (18.1) 229 (16.0)
55 to 59 269 (16.5) 265 (18.5)
60 to 64 258 (15.8) 229 (16.0)
Racea
Caucasian 1143 (70.1) 987 (68.8)
African-American 488 (29.9) 448 (31.2)
Menopausal status
Premenopausal 964 (59.1) 784 (54.6)
Postmenopausal 667 (40.9) 651 (45.4)
History of breast cancera
First-degree family history 610 (37.4) 338 (23.6)
No first-degree family history 969 (59.4) 1057 (73.7)
Adopted or unknown first degree 52 (3.2) 40 (2.8)
Body mass index (kg/m2)
Underweight (<18.5) 31 (1.9) 40 (2.8)
Normal (18.5 to 24.9) 898 (55.3) 726 (50.7)
Overweight (25.0 to 29.9) 436 (26.8) 384 (26.8)
Obese (≥30) 260 (16.0) 283 (19.8)
Oral contraceptive use
Never 358 (22.0) 274 (19.1)
Former 1190 (73.0) 1098 (76.5)
Current 82 (5.0) 63 (4.4)
Unopposed estrogen hormone therapy useb
Never 1004 (61.6) 816 (56.9)
Former 130 (8.0) 129 (9.0)
Current (within 6 months) 206 (12.6) 245 (17.1)
Estrogen plus progestin hormone therapy useb
Never 1004 (61.6) 816 (56.9)
Former 75 (4.6) 91 (6.3)
Current (within 6 months) 241 (14.8) 187 (13)
Smoking status
Ever 893 (54.8) 769 (53.6)
Never 738 (45.2) 666 (46.4)
Proportions in this table reflect the over-sampling of younger cases, African American cases, and women with a family history of breast cancer. 
Values are expressed as n (%). aCases and controls were sampled according to race, age, study site, and family history of breast cancer. 
bPercentages do not sum to 100% because of missing values.Breast Cancer Research    Vol 9 No 6    Trabert et al.
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ation between polymorphisms in BsmI or Poly(A) and breast
cancer risk.
Smoking status significantly modified the association between
the BsmI genotype and breast cancer risk among postmeno-
pausal Caucasian women (P = 0.04). Among postmenopausal
Caucasian women who reported never smoking, the risk for
breast cancer in carriers of one or two b alleles was 2.2 times
greater than for BB carriers (OR = 2.2, 95% CI = 1.3 to 3.9),
whereas among ever smokers (current or former) the risk for
breast cancer was unrelated to BsmI genotype. Smoking sta-
tus did not significantly modify the association between BsmI
genotype and breast cancer risk among premenopausal Cau-
casian women (P = 0.21).
Among premenopausal African-American women the P value
for interaction between genotype and smoking status was sig-
nificant (P = 0.04) whereas the P value for the interaction
approached but did not achieve significance for postmeno-
pausal African-American women (P = 0.08). Among postmen-
opausal African-American women who reported never
smoking, the risk for breast cancer for carriers of one or two b
alleles compared with individuals carrying the BsmI BB geno-
type was increased, albeit not statistically significantly (OR =
1.8, 95% CI = 0.7 to 4.9), whereas among premenopausal
African-American women who reported never smoking the risk
for breast cancer in carriers of one or two b alleles was signif-
icantly decreased compared with BB carriers (OR = 0.4, 95%
CI = 0.2 to 0.9).
Table 2
Genotype and allele proportions for breast cancer risk associated with BsmI and Poly(A) genotypes
Genotype Controlsa (n [%]) Allele frequency Casesa (n [%]) Allele frequency ORb (95% CI)
BsmI
All B/B 308 (21.7) 345 (20.6) 1.0 (referent)
B/b 539 (37.2) B 0.41 606 (37.2) B 0.40 1.1 (0.9 to 1.3)
b/b 564 (41.0) b 0.59 670 (42.2) b 0.60 1.1 (0.9 to 1.4)
any b 1,103 (78.3) 1,276 (79.4) 1.2 (0.9 to 1.3)
Caucasian B/B 258 (27.3) 278 (24.5) 1.0 (referent)
B/b 371 (38.2) B 0.46 432 (37.9) B 0.43 1.1 (0.9 to 1.4)
b/b 336 (34.5) b 0.54 426 (37.5) b 0.57 1.2 (0.9 to 1.6)
any b 707 (84.4) 858 (84.8) 1.2 (0.9 to 1.4)
African American B/B 50 (11.7) 67 (13.3) 1.0 (referent)
B/b 168 (35.5) B 0.30 174 (36.0) B 0.32 0.9 (0.6 to 1.4)
b/b 228 (52.8) b 0.70 244 (50.7) b 0.68 0.9 (0.5 to 1.3)
any b 390 (88.4) 406 (86.7) 0.9 (0.6 to 1.3)
Poly(A)
All S/S 176 (12.6) 202 (13.1) 1.0 (referent)
L/S 651 (45.9) S 0.36 713 (44.2) S 0.35 0.9 (0.7 to 1.2)
L/L 575 (41.4) L 0.64 665 (42.7) L 0.65 1.0 (0.8 to 1.3)
any L 1,226 (87.4) 1,378 (86.9) 1.0 (0.8 to 1.2)
Caucasian S/S 149 (15.6) 167 (15.2) 1.0 (referent)
L/S 402 (49.5) S 0.39 532 (46.1) S 0.38 1.0 (0.7 to 1.3)
L/L 354 (34.9) L 0.61 440 (38.7) L 0.62 1.1 (0.8 to 1.5)
any L 836 (72.7) 972 (75.5) 1.0 (0. 8 to 1.4)
African American S/S 27 (6.8) 35 (8.9) 1.0 (referent)
L/S 169 (39.0) S 0.27 181 (40.5) S 0.28 0.8 (0.5 to 1.5)
L/L 221 (54.2) L 0.73 225 (50.6) L 0.72 0.7 (0.4 to 1.3)
any L 396 (93.2) 418 (91.1) 0.8 (0.4 to 1.4)
aProportions are weighted for age, race, study site, and first-degree family history sampling probabilities. bOdds ratio (OR) adjusted for age, race, 
study site, and sampling weights. CI, confidence interval.Available online http://breast-cancer-research.com/content/9/6/R84
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Smoking status also significantly modified the association
between  Poly(A)  genotype and breast cancer risk among
postmenopausal Caucasian women (P = 0.02). Among post-
menopausal Caucasian women who reported never smoking,
the risk for breast cancer for carriers of any L allele was 2.3
times greater than that for carriers of the Poly(A) SS genotype
(OR = 2.3, 95% CI = 1.2 to 4.3), whereas among never smok-
ers the risk for breast cancer was unrelated to Poly(A) geno-
type (OR = 0.7, 95% CI = 0.4 to 1.2).
In terms of the main effect of smoking, premenopausal Cauca-
sian women who reported ever smoking had a statistically sig-
nificant increased risk for breast cancer (OR = 1.4, 95% CI =
1.1 to 1.8) as compared with women who reported never
smoking. Smoking was not associated with an increased risk
for breast cancer among postmenopausal Caucasian women,
premenopausal African-American women, or postmenopausal
African-American women.
Discussion
Within the CARE study population, we observed a slight
increase in risk for breast cancer among postmenopausal
Caucasian women with the BsmI bb genotype. There was little
evidence of a similar relationship in premenopausal or African-
American women. In addition, there was no evidence of a rela-
tionship between the Poly(A) LL genotype and risk for breast
cancer overall, or within any racial or menopausal status sub-
group. We do note that genotype frequencies were different
by menopausal status; however, there is no biologic explana-
tion for this difference. Automated genotyping systems, to the
degree that they are flawed, have a tendency to overcall
homozygotes and undercall heterozygotes, but there is no rea-
son to assume that bb or BB genotypes would be differentially
miscalled according to any exposure, including menopausal
status. This observation does not change the overall conclu-
sions of the study, and the differing results for premenopausal
and postmenopausal Caucasian women are probably
accounted for by small numbers.
Prior studies of VDR and breast cancer risk have been limited
in number and yielded inconsistent results. Three hospital-
based case-control studies of Caucasian women in the UK
reported an increased risk for breast cancer in carriers of BsmI
bb genotype [3,10,16]. However, these reports appear likely
to involve overlapping populations. All three studies involved
the same core group of authors and included patients from St.
George's Hospital Medical School in London. Two used con-
trols from the UK National Breast Screening Programme
[10,16], whereas the third used controls from a screening
clinic [3]. The largest of these studies [16] included 398 inci-
dent and prevalent breast cancer cases and 427 screened,
disease-free controls. The investigators reported a 1.9-fold
Table 3
Odds ratios and 95% confidence intervals for breast cancer risk associated with BsmI and Poly(A) genotypes, stratified by race and 
menopausal status
Genotype Menopausal status Caucasian African-American
Case (%) Control (%) ORa (95% CI) Case (%) Control (%) ORa (95% CI)
BsmI B/B Premenopausal 164 (25.3) 133 (25.8) 1.0 (referent) 38 (12.1) 22 (9.6) 1.0 (referent)
B/b 244 (36.9) 198 (36.0) 1.1 (0.8 to 1.5) 108 (34.6) 90 (36.7) 0.8 (0.4 to 1.4)
b/b 247 (37.8) 199 (38.1) 1.0 (0.7 to 1.4) 156 (53.3) 126 (53.7) 0.8 (0.4 to 1.5)
Any b 491 (74.7) 397 (74.2) 1.0 (0.8 to 1.4) 264 (87.9) 216 (90.4) 0.8 (0.4 to 1.4)
B/B Postmenopausal 114 (23.5) 125 (29.2) 1.0 (referent) 29 (15.2) 28 (14.3) 1.0 (referent)
B/b 188 (39.3) 173 (40.9) 1.2 (0.8 to 1.8) 66 (38.0) 78 (34.0) 1.0 (0.5 to 2.0)
b/b 179 (37.2) 137 (30.0) 1.5 (1.0 to 2.3)b 88 (46.8) 102 (51.7) 0.9 (0.5 to 2.0)
Any b 367 (76.5) 310 (70.8) 1.4 (1.0 to 1.9) 154 (84.8) 180 (85.7) 1.0 (0.5 to 1.8)
Poly(A) S/S Premenopausal 98 (15.7) 79 (15.4) 1.0 (referent) 23 (9.1) 14 (6.8) 1.0 (referent)
L/S 303 (45.3) 260 (47.3) 0.9 (0.6 to 1.4) 109 (39.6) 88 (39.2) 0.8 (0.4 to 1.7)
L/L 256 (39) 203 (37.3) 1.0 (0.7 to 1.5) 144 (51.3) 118 (54.1) 0.7 (0.3 to 1.6)
Any L 559 (84.3) 463 (84.6) 1.0 (0.7 to 1.4) 253 (90.9) 206 (93.3) 0.7 (0.4 to 1.6)
S/S Postmenopausal 69 (14.5) 70 (15.8) 1.0 (referent) 12 (8.5) 13 (6.8) 1.0 (referent)
L/S 229 (47.2) 222 (52.2) 1.0 (0.7 to 1.6) 72 (41.9) 81 (38.9) 0.8 (0.3 to 2.1)
L/L 184 (38.3) 151 (31.9) 1.3 (0.9 to 2.1) 81 (49.5) 103 (54.3) 0.8 (0.3 to 2.1)
Any L 413 (85.5) 373 (84.2) 1.2 (0.8 to 1.8) 153 (91.5) 184 (93.2) 0.8 (0.3 to 2.0)
aOdds ratio (OR) adjusted for age, race, study site, and sampling weights. bP for trend <0.05.Breast Cancer Research    Vol 9 No 6    Trabert et al.
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increased risk for breast cancer among carriers of the BsmI bb
genotype, and a nearly twofold increase in risk for carriers of
the Poly(A) LL genotype, when controlling for age, HT, and
menopausal status. Participants were matched for age at sam-
pling (controls) versus diagnosis (cases), but they differed sig-
nificantly in terms of menopausal status and HT use. The
second study [10] included 181 breast cancer cases and 241
controls from the same two institutions described above.
Cases were not age-matched to controls. Controls were con-
firmed as having no detectable cancer at the time of sampling,
although 89 had 'other' breast conditions such as calcifica-
tions, fibrocystic disease, or benign lumps. The authors
reported a more than twofold increase in risk for breast cancer
associated with both the BsmI bb genotype and Poly(A) LL
genotype. The differences between this study and our own
population-based study are significant, limiting our ability to
compare results. The third study [3] was distinguished by the
fact that the investigators also measured serum 25-hydroxyvi-
tamin D levels. In this hospital-based, case-control study of
179 cases matched to 179 disease-free control volunteers by
age, menopausal status (where possible), and time of year, a
significant doubling in the risk for breast cancer was observed
in women with BsmI bb compared with those with the BB gen-
otype. The authors concluded that low circulating 25-hydroxy-
vitamin D levels, either alone or in combination with the BsmI
Bb or bb genotype, may increase breast cancer risk.
In contrast, several prior studies did not report an increased
risk for breast cancer associated with either the BsmI bb gen-
otype or the Poly(A) LL genotype [17-20,28]. One of the larg-
est, that conducted by Chen and colleagues [18], was
conducted to investigate the role played by VDR polymor-
phisms and breast cancer risk in a nested case-control study
of largely Caucasian women aged 43 to 69 years within the
Nurses' Health study. The authors genotyped 1,180 cases
and 1,547 controls for the BsmI and 1,234 cases and 1,676
controls for the Fok1 polymorphisms. They observed a signifi-
cantly increased risk for breast cancer among carriers of the ff
genotype of Fok1 (OR = 1.34, 95% CI = 1.06 to 1.69) as
compared with those with the FF genotype, but they found no
association between the BsmI polymorphism and breast can-
cer risk (OR = 0.93; 95% CI = 0.72 to 1.20) for BB versus bb.
The conclusions did not change when the data were stratified
by menopausal status. The Poly(A) variant was not tested.
To our knowledge, no prior studies of the VDR polymorphism
and breast cancer risk have included a substantial number of
African-American women. It is important to note that we did
not observe a statistically significant increased risk for breast
cancer associated with either the BsmI bb genotype or the
Poly(A) LL genotype among the African-American women in
our study. The (nonsignificant) reduced risk for breast cancer
associated with carrying either the BsmI Bb or bb genotypes
among never smokers, observed in African-American women,
was probably due to small numbers in the referent category
and not the presence of the allele or the effect of not smoking.
Significantly larger studies of African-American women would
be needed to address that question more completely.
Genetic factors such as the VDR polymorphism that influence
disease risk may be subject to environmental influences. For
example, smoking is an inconsistent risk factor for breast
cancer [29], but the effects of polymorphisms in other genes
on breast cancer risk have been observed to vary by smoking
history [30,31]. Although not consistent in all subgroups, we
did observe that the presence of any b allele elevated the risk
for breast cancer among never smokers and that the relation-
ship between the VDR polymorphisms and breast cancer risk
varied among postmenopausal Caucasian women who
reported ever or never smoking. The effect modification results
should, however, be interpreted with caution; although we did
observe an association between breast cancer and the BsmI
bb genotype among postmenopausal Caucasian women, we
did not observe an association between breast cancer and
smoking in the same subgroup.
Vitamin D itself is proposed to have anticancer properties [32-
34]. Indeed, it has been shown that calcitriol (1,25-dihydroxy-
vitamin D3), a hormonal derivative of vitamin D3, has an
antiproliferative and prodifferentiation effect on several cell
types, specifically the squamous cells of the head and neck
[35]. In a study of prostate cancer, Ma and coworkers [13]
reported that vitamin D intake modified the risk for prostate
cancer that was associated with VDR polymorphism (BsmI).
Specifically, they observed a 57% reduction in risk among
men with a plasma 25-hydroxyvitamin D level below the
median who had the BB versus bb genotype (relative risk =
0.43, 95% CI = 0.19 to 0.98). The risk reduction was strong-
est among older men (relative risk = 0.18, 95% CI = 0.05 to
0.68).
We did not have information on vitamin D levels, via either die-
tary intake or metabolism from routine sun exposure. However,
several studies [7-9] support a relationship between an
increase in breast cancer risk and bone density. Two prospec-
tive cohort studies have reported an association between
greater bone mass and breast cancer risk [7,8], and one of
these studies suggests that vitamin D intake can modify the
risk of osteoporosis in women being treated for breast cancer
[7]. In addition, men undergoing androgen ablation therapy
experience osteoporosis [36,37], which also supports a rela-
tionship between sex hormones and bone modeling. It is pos-
sible that the increased bone density observed in women with
an increased risk of breast cancer may simply be a marker for
high levels of vitamin D uptake, reflecting specific vitamin D
receptor genotypes, or perhaps a marker of higher levels of
endogenous estrogens.
Our data support a role for the BsmI b allele in the develop-
ment of breast cancer in women who never smoked, but not inAvailable online http://breast-cancer-research.com/content/9/6/R84
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those who did smoke. Why a subset of VDR genotypes would
have a differential effect on smokers versus nonsmokers is
unclear. One hypothesis is that there is some as yet undefined
interaction between estrogen metabolism and smoking that is
exacerbated by specific levels of vitamin D status.
The strengths of the present study include its large size, gen-
eralizability, and the ability to control for most of the estab-
lished risk factors for breast cancer. To date, this is the largest
study of VDR polymorphisms and breast cancer risk. The pop-
ulation-based design, wider age range, and inclusion of both
African-American and Caucasian women allow a more com-
prehensive portrayal of the frequency of mutations in the gen-
eral population than has been available to date. Despite the
generous sample size, the number of women with referent
genotypes was small, resulting in an inability to make precise
estimates. In addition, the study was limited by the fact that the
gene was interrogated at only two positions at the 3' end of the
gene. Newer technologies now permit a more comprehensive
approach to genotyping, and variation within the entire gene
will be readily examined in subsequent studies. The departure
from Hardy-Weinberg equilibrium that we observed for the
BsmI polymorphism could be attributed to any number of fac-
tors, including undetected ethnic diversity, biologic explana-
tions, or genotyping misclassifications. We did not include
blinded duplicates in the genotyping dataset, and therefore we
did not have the opportunity to check for systematic genotyp-
ing errors.
One difficulty in studies of single nucleotide polymorphisms,
such as this, is the issue of whether the variant being tested is
truly associated with the disease or whether there is another
polymorphism in linkage disequilibrium with the polymorphism
under consideration that could be responsible for the
observed association. Only when the whole gene can be
examined along with associated regulatory elements can we
develop a clearer picture of the underlying biology that con-
sistently links the VDR gene to cancer risk.
Conclusion
This study provides additional support for an increased risk for
breast cancer associated with the BsmI polymorphism at the
3' end of the VDR gene in postmenopausal Caucasian women
and sheds light on the differential risk observed in menopausal
status and race. Contributions of vitamin D intake to risk for
breast cancer and bone mineral density, as well as potential
effect modification by history of smoking, should be further
studied to elucidate the precise biologic mechanisms.
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